Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ethynylcytidine is a nucleoside antimetabolite.
Description | Ethynylcytidine is a nucleoside antimetabolite. |
In vitro | The cytotoxicity of Ethynylcytidine tends to become stronger as the exposure time becomes longer. The IC50 values of Ethynylcytidine in the five human tumors with 4, 24 and 72 h exposure range from 0.114 to 1.032 μM, 0.015 to 0.067 μM, and 0.008 to 0.058 μM, respectively. The differences in IC50 values between the 24 and 72 h exposure times are not large, and Ethynylcytidine appears to show sufficiently potent cytotoxicity at the 24 h exposure time in all 5 human tumors. |
In vivo | In both OCUM-2MD3 and LX-1 xenograft models, Ethynylcytidine exhibits significant tumor regression and potent antitumor efficacy, achieving a tumor growth inhibition (IR) rate of around 90% or higher by day 15 at minimally toxic doses across all three dosing schedules. A weekly administration of Ethynylcytidine at 6 mg/kg results in a substantial reduction in LX-1 tumor size, with an IR of 98%. Conversely, administering Ethynylcytidine three or five times weekly yields a strong antitumor response with an IR of approximately 85%, while a once-weekly treatment results in an IR of less than 60%, indicating comparatively weaker antitumor activity. |
Alias | TAS-106, ECyD, 3'-C-Ethynylcytidine |
Molecular Weight | 267.24 |
Formula | C11H13N3O5 |
Cas No. | 180300-43-0 |
Relative Density. | 1.61 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 240 mg/mL (898.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.